Thiel's Breakout Labs adds cash backer for life science ventures; Sanofi subsidiary buys stake in Alnylam;

@FierceBiotech: Startup scPharmaceuticals snags $16M for self-dosed injectables. Read | Follow @FierceBiotech

@JohnCFierce: Fierce readies a new weekly report on the European biotech scene. Details | Follow @JohnCFierce

@DamianFierce: Sanofi bets big on dengue with eyes on a blockbuster. More | Follow @DamianFierce

@EmilyMFierce: Most read at yesterday: Amylin diabetes drug improves learning, memory in Alzheimer's mice. Story | Follow @EmilyMFierce

> The investment group NetScientific is backing Peter Thiel's philanthropic Breakout Labs' seed investments of new tech companies with $250,000 in follow-on cash. "Over the past two years Breakout Labs has proven new funding models that help advance research out of the lab and into the world at large are sorely needed," said Farad Azima, CEO of NetScientific. "This partnership provides NetScientific with access to some of the most revolutionary new technologies coming out of Silicon Valley and beyond. We're impressed by Breakout Lab's ability to identify and foster revolutionary life science companies and look forward to working with them to help support a new wave of scientific innovation." Release

> Sanofi's ($SNY) Boston-based subsidiary Genzyme has exercised its rights to buy a stake of Alnylam ($ALNY), completing a deal with the RNAi biotech announced at JP Morgan in January. Release

Medical Device News

@FierceMedDev: More legal action is in the mix against Intuitive over its robotic surgical device. Story | Follow @FierceMedDev

@MarkHFierce: The latest FierceDiagnostics is ready for you, featuring details on an IPO, cancer Dx and Alzheimer's biomarkers. Report | Follow @MarkHFierce

@MichaelGFierce: Arrowhead doses first RNAi hepatitis B 'functional cure' PhIIa patient. More from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Tiny recorder helps parents communicate with children, and could spur brain development. Article | Follow @EmilyWFierce

> Did J&J intentionally destroy documents relevant to patients' vaginal mesh lawsuits? Story

> GE Healthcare will supply cancer Dx tools in new Indian care clinics. News

Pharma News

@FiercePharma: Just out: today's full issue of FiercePharmaMarketing. More | Follow @FiercePharma

@TracyStaton: Anti-inflammatories rule! Top 3 best-selling drugs last year = Humira, Enbrel + Remicade. Report | Follow @TracyStaton

@EricPFierce: AmerisourceBergen global expansion continues with $100M deal for a 20% stake in Brazil's Profarma. Article | Follow @EricPFierce

@CarlyHFierce: AstraZeneca, Pfizer say direct-delivery programs can win with patients. Story | Follow @CarlyHFierce

> AstraZeneca takes control of its destiny in Japan with buyout. Article

> GlaxoSmithKline yanks European app for Tafinlar-Mekinist combo in melanoma. Story

> GlaxoSmithKline flags product tampering as wrong pills surface in alli packages. More

> Florida man threatened to poison J&J products unless it forked over cash. News

Drug Delivery News

> Arrowhead doses first RNAi hepatitis B 'functional cure' PhIIa patient. News

> Nasal spray for depression offers minimally invasive treatment option. Story

> FDA accepts Avanir's inhaled migraine treatment application. News

> Small, drug-releasing battery could dissolve completely over time. Article

> Clumps of gold nanoparticles retain heat or drugs to kill cancer cells. Story

> Alexza secures $45 million from investors based on U.S. Adasuve sales. Brief

Diagnostics News

> Ariosa Diagnostics mulls an IPO worth up to $69M. News

> Foundation Medicine seeks up to $150M to keep its cancer Dx growth engine running. Story

> CTC levels could provide a prostate cancer survival clue. Article

> Mobile app could offer inexpensive Dx in developing world. Story

> Two Alzheimer's biomarker studies spur hope for earlier-stage diagnosis. Story

> Four new biomarkers may enable an earlier stomach cancer diagnosis. Brief

Pharma Marketing News

> ASCO plans cost-benefit scorecard for cancer meds as prices grow 'unsustainable.' Story

> Pharma is a 'design industry,' expert says. So why don't all Big Pharmas have CDOs? Article

> Astellas presents The Bladder, animated pitch-organ for overactive-bladder med Myrbetriq. Story

> AstraZeneca, Pfizer say direct-delivery programs can win with patients. Article

> Great expectations: Patients think pharma owes them apps, rewards, and more. Piece

> AstraZeneca, Sanofi tap mobile providers for patient-monitoring services. Brief

Suggested Articles

When it’s time to go public, most biotech companies for the Nasdaq. Not so for SQZ Biotech, which raised $71 million in its NYSE debut.

The saga of COVID antibody R&D continues as the REGN-COV2 antibody cocktail used by President Donald Trump has been hit by safety concerns.

A Dartmouth-led team proposed a method for targeting and inhibiting the most aggressive cells in breast tumors to improve responses to chemotherapy.